No Data
On December 12, LIVZON PHARMA (01513.HK) spent 0.196 million HKD to repurchase 7,100 shares.
Gelonghui, December 12丨LIVZON PHARMA (01513.HK) announced that on December 12, it spent 0.196 million Hong Kong dollars to repurchase 7,100 shares.
LIVZON PHARMA (01513.HK) spent 3.997 million Hong Kong dollars to buy back 0.144 million shares on December 11.
Gelonghui reported on December 11 that LIVZON PHARMA (01513.HK) announced that on December 11, it spent 3.997 million HKD to repurchase 0.144 million shares.
LIVZON PHARMA (01513.HK) spent 9.919 million Hong Kong dollars to repurchase 0.36 million shares on December 10.
On December 10, Gelonghui announced that LIVZON PHARMA (01513.HK) spent HKD 9.919 million to repurchase 0.36 million shares.
Announcement highlights | Longfor Group's sales exceeded 90 billion yuan this year; Mao Geping announced the lottery results, listed this morning.
In the first 11 months, longfor group achieved a total contract sales amount of 93 billion yuan, with contract sales of 8.5 billion yuan in November; cspc pharma's application for marketing approval for SYHX2011 to treat advanced breast cancer was accepted.
Livzon pharmaceutical group inc. (000513.SZ): The buyback has been completed, with a total of 1.78% of shares repurchased.
On December 9, Gelonghui reported that Livzon Pharmaceutical Group Inc. (000513.SZ) announced that as of December 6, 2024, the company had repurchased a total of 16,474,564 A shares through centralized bidding, accounting for 1.78% of the company's total share capital. The highest purchase price was 37.96 yuan/share, and the lowest was 32.95 yuan/share, with a total amount of 0.5998 billion yuan used (excluding transaction costs). The company has completed the repurchase according to the established plan.
Livzon Pharma (01513.HK): Livzon monoclonal antibody signed a patent and technology transfer agreement for the influenza recombinant protein vaccine project with South China Vaccine.
On December 9, according to a report from Gelonghui, Livzon Pharma (01513.HK) announced that recently, its holding subsidiary Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd. (Livzon Monoclonal Antibody) signed a "Patent and Technology Transfer Agreement for the Influenza Recombinant Protein Vaccine Project" with Guangdong South China Vaccine Co., Ltd. (South China Vaccine). According to the agreement, South China Vaccine intends to transfer the project rights for the trivalent influenza recombinant protein vaccine and/or quadrivalent influenza recombinant protein vaccine, which is the final sales form developed based on the project technology, to Livzon Monoclonal Antibody, and Livzon Monoclonal Antibody needs to pay South China Vaccine the corresponding patent and technology transfer fees (including the down payment, development milestones).
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
